Biosimilar to Trastuzumab

About Shenzhen Salubris Pharmaceuticals

Founded in 1998, Shenzhen Salubris Pharmaceuticals has grown from a domestic manufacturer into a Chinese biopharmaceutical leader with a significant public valuation. Its mission centers on addressing critical healthcare needs in chronic diseases through a dual strategy of high-quality generic production and innovative drug development. Key achievements include establishing dominant market positions in cardiovascular and metabolic segments, building a robust pipeline with several late-stage assets, and maintaining consistent profitability to fund R&D. The company's strategy focuses on deepening its therapeutic moats, expanding its innovative portfolio, and navigating the evolving Chinese pharmaceutical reimbursement landscape.

Therapeutic Areas

Other HER2+ Breast Cancer Drugs